3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics

Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's shares are up by 610% over the last three years, Altimmune's are down by 54%.However, there's more than one argument for why Altimmune's next act could look a lot more like Viking's trajectory. So let's examine three reasons it might be the next weight loss biotech to soar.If you've been keeping up with the biopharmaceutical sector lately, you know that weight loss drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy are all the rage. Per the World Health Organization (WHO), by 2025, nearly 1 billion people globally will fit the criteria for obesity.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Zum vollständigen Artikel